Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference

Apr 07, 2022

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Apr 04, 2022

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Apr 04, 2022

Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Apr 04, 2022

Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022

Apr 01, 2022

Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights

Mar 28, 2022

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 28, 2022

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 23, 2022

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 23, 2022

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting

Mar 21, 2022
RSS
  • Prev
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...57
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap